Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony Tolcher, M.D., to advise Bright Peak in its mission to develop next-generation multifunctional precision immunotherapies for cancer –
October 18, 2022 — SAN DIEGO, California & BASEL, Switzerland — Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein engineering platform to develop next-generation multifunctional cytokine-based immunotherapies, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in immuno-oncology basic, translational and clinical research.
“Bright Peak is truly privileged and excited to have such an accomplished and dedicated group of scientific and clinical experts to advise on our discovery and clinical development programs,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak. “Their combined resume includes some of the most groundbreaking discoveries in immuno-oncology, from basic biology through clinical investigation.” Jon Wigginton, M.D., President of Research and Development at Bright Peak added, “We are honored to welcome this outstanding group of investigators to the Bright Peak SAB and look forward to leveraging their expertise in our shared mission to develop transformative precision immunotherapies that address significant unmet needs for patients with cancer.”